These results suggest that combination of refametinib plus pictilisib is more effective than lapatinib plus trastuzumab combined treatment and that the addition of anti-HER2 drugs to MEK and PI3KCA inhibitors does not significantly increase cell growth inhibition in these HER2-amplified colon cancer models. The gene discussed is MAP2K7; the disease is malignant colon neoplasm.